Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.

Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.

A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.

Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.